Kraig Biocraft Laboratories (KBLB) S-1/A 23 Mar 22 IPO registration (amended) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2021
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	AMENDMENT No. 1
Entity Registrant Name	KRAIG BIOCRAFT LABORATORIES, INC.
Entity Central Index Key	0001413119
Entity Tax Identification Number	83-0459707
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	2723 South State St. Suite 150
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48104
City Area Code	(734)
Local Phone Number	619-8066
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Kim Thompson, CEO
Entity Address, Address Line Two	2723 South State St., Suite 150
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48104
City Area Code	(734)
Local Phone Number	619-8066

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash	$ 2,355,060	$ 816,907
Prepaid expenses	11,055	2,588
Total Current Assets	2,366,115	819,495
Property and Equipment, net	110,943	89,247
Investment in gold bullions (cost $450,216 and $0, respectively)	437,212
Operating lease right-of-use asset, net	104,124	365,025
Security deposit	3,518	3,518
Total Assets	3,021,912	1,277,285
Current Liabilities
Accounts payable and accrued expenses	587,794	600,003
Note payable - related party	1,657,000	1,657,000
Royalty agreement payable - related party	65,292	65,292
Accounts payable and accrued expenses - related party	5,244,560	4,802,985
Operating lease liability, current	44,577	124,909
Loan payable	60,000	60,000
Convertible note payable, net of debt discount of $246,577 and $949,945, respectively	503,423	50,505
SBA Paycheck Protection Loan		90,100
Total Current Liabilities	8,162,646	7,450,794
Long Term Liabilities
Loan payable, net of current	95,244	145,244
Operating lease liability, net of current	59,897	254,811
Total Liabilities	8,317,787	7,850,849
Commitments and Contingencies
Stockholders’ Deficit
Preferred stock value
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000
Additional paid-in capital	9,894,179	5,833,583
Accumulated Deficit	(42,814,986)	(34,769,183)
Total Stockholders’ Deficit	(5,295,875)	(6,573,564)
Total Liabilities and Stockholders’ Deficit	3,021,912	1,277,285
Series A Preferred Stock [Member]
Stockholders’ Deficit
Preferred stock value	5,217,800	5,217,800
Common Class A [Member]
Stockholders’ Deficit
Common Stock Value	22,385,132	17,122,236
Common Class B [Member]
Stockholders’ Deficit
Common Stock Value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Investment cost	$ 450,216	$ 0
Debt discount, net	$ 246,577	$ 949,945
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	Unlimited	Unlimited
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock issuable	1,122,311	1,122,311
Series A Preferred Stock [Member]
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares issued	2	2
Preferred stock, shares outstanding	2	2
Common Class A [Member]
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	927,378,166	854,410,001
Common stock, shares outstanding	927,378,166	854,410,001
Common Class B [Member]
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue
Operating Expenses
General and Administrative	1,496,725	3,518,527
Professional Fees	326,982	397,727
Officer’s Salary	734,427	516,332
Rent - Related Party	3,683	13,092
Research and Development	197,745	88,470
Total Operating Expenses	2,759,562	4,534,148
Loss from Operations	(2,759,562)	(4,534,148)
Other Income/(Expenses)
Gain on debt extinguishment (PPP)	90,100
Net change in unrealized depreciation on investment in gold bullion	(13,004)
Interest expense	(660,419)	(386,624)
Amortization of original issue discount	(4,702,918)	(50,505)
Total Other Income/(Expenses)	(5,286,241)	(437,129)
Net (Loss) before Provision for Income Taxes	(8,045,803)	(4,971,277)
Provision for Income Taxes
Net (Loss)	$ (8,045,803)	$ (4,971,277)
Net Income (Loss) Per Share - Basic and Diluted	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding during the period - Basic and Diluted	877,612,187	848,651,465

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities:
Net Loss	$ (8,045,803)	$ (4,971,277)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense	26,137	28,074
Gain on debt extinguishment (PPP)	(90,100)
Net change in unrealized depreciation in gold bullions	13,004
Stock issued for services	242,100
Loss on disposal of fixed assets	49,321
Amortization of debt discount	4,702,918	50,505
Imputed interest - related party	82,851	58,817
Fair value of options issued for services		2,845,459
Warrants issued/(cancelled) to consultants	600,278
Changes in operating assets and liabilities:
Decrease (Increase) in prepaid expenses	(8,467)	29,157
Operating lease right-of-use, net	90,072	108,217
Increase in accrued expenses and other payables - related party	441,574	657,520
(Decrease)Increase in accounts payable	199,723	39,055
Operating lease liabilities, current	(104,417)	(100,239)
Net Cash Used In Operating Activities	(1,800,809)	(1,254,712)
Cash Flows From Investing Activities:
Investment in gold bullions	(450,216)
Purchase of Fixed Assets	(97,154)
Net Cash Used In Investing Activities	(547,370)
Cash Flows From Financing Activities:
Proceeds from notes payable - related party		1,015,000
Proceeds from convertible note payable, net of original issue discount	3,670,000	950,000
Payment of debt offering costs		(86,000)
Principal payments on debt	(50,000)	(40,000)
Proceeds from warrant exercise	266,332
Contributed capital - related party		17,495
Proceeds from SBA Paycheck Protection Loan		90,100
Net Cash Provided by Financing Activities	3,886,332	1,946,595
Net Increase in Cash	1,538,153	691,883
Cash at Beginning of Year	816,907	125,024
Cash at End of Year	2,355,060	816,907
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise	292,533	365,157
Beneficial conversion feature in connection with convertible debt	3,670,000	864,000
Original issue discount in connection with convertible debt		50,000
Shares issued in connection with convertible note payable	4,461,931
Adoption of lease standard ASC 842	115,390
Cancellation and forgiveness of lease - related party	44,419
Cancellation and forgiveness of lease	$ 241,800

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders Deficit - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Common Class A Stock [Member]	Common Class B Stock [Member]	Common Stock Class A Shares To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	$ 2,412,969	$ (29,797,906)	$ (5,388,058)
Balance, shares at Dec. 31, 2019	2	844,468,378		1,122,311
Warrants issued for services - related parties					2,794,696		2,794,696
Warrants issued for services					50,763		50,763
Exercise of warrants in exchange for stock		$ 365,157			(365,157)
Exercise of warrants in exchange for stock, shares		9,941,623
Contributed capital - related party					17,495		17,495
Imputed interest - related party					58,817		58,817
Beneficial conversion feature					864,000		864,000
Net loss						(4,971,277)	(4,971,277)
Ending balance, value at Dec. 31, 2020	$ 5,217,800	$ 17,122,236		$ 22,000	5,833,583	(34,769,183)	(6,573,564)
Balance, shares at Dec. 31, 2020	2	854,410,001		1,122,311
Warrants issued for services - related parties					556,276		556,276
Warrants issued for services					86,709		86,709
Cancellations of warrants					(42,707)		(42,707)
Exercise of warrants in exchange for stock		$ 558,865			(292,533)		266,332
Exercise of warrants in exchange for stock, shares		5,296,250
Convertible debt conversion into common stock ($0.0744 - $0.1540/Sh)		$ 4,461,931					4,461,931
Convertible debt conversion into common stock, shares		64,671,915
Common stock issued for services		$ 242,100					242,100
Common stock issued for services, shares		3,000,000
Imputed interest - related party					82,851		82,851
Beneficial conversion feature					3,670,000		3,670,000
Net loss						(8,045,803)	(8,045,803)
Ending balance, value at Dec. 31, 2021	$ 5,217,800	$ 22,385,132		$ 22,000	$ 9,894,179	$ (42,814,986)	$ (5,295,875)
Balance, shares at Dec. 31, 2021	2	927,378,166		1,122,311

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Stockholders Deficit (Parenthetical)	12 Months Ended
	Dec. 31, 2021$ / shares
Minimum [Member]
Conversion price per share	$ 0.0744
Maximum [Member]
Conversion price per share	$ 0.1540

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Ogranization Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date. Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2021 and 2020, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2021 and 2020 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2021 December 31, 2020 Stock Warrants (Exercise price - $ 0.001 0.25 48,972,277 49,120,917 Stock Options (Exercise price - $ 0.1150 26,802,500 27,340,000 Convertible Debt 6,470,674 - Convertible Preferred Stock 2 2 Total 82,245,453 76,460,919 Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Expected income tax (recovery) expense at the statutory rate of 21 $ (1,689,619 ) $ (1,043,948 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 1,141,619 608,152 Change in valuation allowance 548,000 435,795 Provision for income taxes $ - $ - The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES 2021 2020 Years Ended December, 2021 2020 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 4,363,336 3,815,336 Valuation allowance (4,343,336 ) (3,815,336 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2041. The net change in the valuation allowance for the year ended December 31, 2021 and 2020 was an increase of $ 548,000 435,795 Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07. Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. In June 2016, the FASB issued ASU 2016-13 - Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments. Codification Improvements to Topic 326, Financial Instruments – Credit Losses, have been released in November 2018 (2018-19), November 2019 (2019-10 and 2019-11) and a January 2020 Update (2020-02) that provided additional guidance on this Topic. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For SEC filers meeting certain criteria, the amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For SEC filers that meet the criteria of a smaller reporting company (including this Company) and for non-SEC registrant public companies and other organizations, the amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early adoption will be permitted for all organizations for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently in the process of its analysis of the impact of this guidance on its financial statements and does not expect the adoption of this guidance to have a material impact on the Company’s financial statements. In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intra period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard will not have a material effect on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, to reduce complexity in applying U.S. GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2023, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard will not have a material effect on the Company’s financial statements. Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2021 and 2020. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2021 December 31, 2020 Level 1 – Investment in Gold $ 437,212 $ - Level 2 $ - $ - Level 3 $ - $ - Total $ 437,212 $ - The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company. Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter. The following tables summarize activity in gold bullion for the year ended December 31, 2021: SCHEDULE OF GOLD IN BULLION Year Ended December 31, 2021 Ounces Cost Fair Value Beginning balance - $ - $ - Investment in Gold bullion 239 1,884 450,216 Net change in unrealized depreciation - - (13,004 ) Ending balance 239 $ 1,884 $ 437,212 Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017 and ending in September 2018, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the years ended December 31, 2021 and 2020, the Company recognized $ 0 0 On January 25, 2021, the Company signed an amendment to a strategic partnership agreement with Kings Group for and exclusive sales agreement for up to $ 40 Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2021 and December 31, 2020, the Company had approximately $ 2,092,420 500,000 Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt. Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument. Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 GOING CONCERN As reflected in the accompanying financial statements, the Company has a working capital deficiency of $ 5,796,531 5,295,875 1,800,809 Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

EQUIPMENT

EQUIPMENT	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
EQUIPMENT	NOTE 3 EQUIPMENT At December 31, 2021 and 2020, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2021 December 31, 2020 Automobile $ 41,805 $ 41,805 Laboratory Equipment 118,890 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 82,739 85,389 Less: Accumulated Depreciation (139,751 ) (141,743 ) Total Property and Equipment, net $ 110,943 $ 89,247 Depreciation expense for the years ended December 31, 2021 and 2020, was $ 26,137 28,074 During the years ended December 31, 2021 and 2020, the Company recorded a loss on disposal of fixed assets of $ 49,321 0

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITITY	12 Months Ended
	Dec. 31, 2021
Right To Use Assets And Lease Liabilitity
RIGHT TO USE ASSETS AND LEASE LIABILITITY	NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On January 23, 2017 the Company signed an 8 year property lease with the Company’s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $ 960 3,683 13,092 44,419 On September 5, 2019, we signed a two-year 5,000 42,000 44,800 42,000 44,800 79,862 79,862 On May 9, 2019 the Company signed a 5 4,560.57 45,150 5 241,800 On July 1, 2021, the Company signed a 5 6,000 8,645 Right to use assets is summarized below: SCHEDULE OF RIGHT USE OF ASSETS December 31, 2021 Right to use assets, net 70,550 Right to use assets, net 33,574 Total $ 104,124 During the year ended December 31, 2021, the Company recorded $ 87,874 Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY December 31, 2021 Operating lease liability, net 70,550 Operating lease liability, net 33,574 Total 104,124 Less: short term portion (44,577 ) Long term position $ 59,897 Lease expense for the year ended December 31, 2021 was comprised of the following: SCHEDULE OF LEASE COST Operating lease expense $ 37,461 Operating lease expense $ 55,834 Operating lease expense – related party $ 3,683

ACCRUED INTEREST _ RELATED PART

ACCRUED INTEREST – RELATED PARTY	12 Months Ended
	Dec. 31, 2021
Accrued Interest Related Party
ACCRUED INTEREST – RELATED PARTY	NOTE 5 ACCRUED INTEREST – RELATED PARTY On June 6, 2016, the Company received a $ 50,000 30,000 100,000 15,000 20,000 15,000 15,000 20,000 26,000 11,000 20,000 3,000 30,000 30,000 20,000 20,000 17,000 100,000 100,000 100,000 100,000 100,000 100,000 150,000 100,000 100,000 100,000 30,000 30,000 35,000 70,000 3 1,657,000 1,657,000 82,851 53,671 50,763 36,562

NOTE PAYABLE

NOTE PAYABLE	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
NOTE PAYABLE	NOTE 6 NOTE PAYABLE On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $ 265,244 10 50,000 1. $ 1,000 2. $ 2,000 3. $ 5,000 4. Final payment of all remaining balance, in the amount of $ 180,224 On July 8, 2021, the Company entered into an amendment to the March 1, 2019 agreement. As of the date of the amendment, the remaining outstanding balance is $ 180,244 1. $ 5,000 2. Final payment of the remaining balance in the amount of $ 115,244 57,622 57,622 On April 16, 2020, the Company, was granted a loan (the “Loan”) from The Huntington National Bank, in the aggregate amount of $ 90,100 April 16, 2020 1 100 90,100

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2021
Convertible Notes
CONVERTIBLE NOTES	NOTE 7 CONVERTIBLE NOTES The Company issued a $ 1,000,000 10 5 50,000 950,000 The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date Additionally, the Company issued 3,125,000 5 2,599,066 SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 1,000,000 The Company also paid $ 86,000 On March 25, 2021, the Company entered into one year, unsecured, convertible note in the aggregate principal amount of $ 4,000,000 500,000 March 25, 2022 10 The note contains a discount to market feature, whereby, the lender can purchase stock at 80% of the lowest trading price for a period of ten (10) days preceding the conversion date 500,000 3,000,000 Additionally, the Company issued 8,000,000 5 3,359,716 Stock Price $ 0.15 Exercise price $ 0.25 Expected term (in years) 5 Expected volatility 100.76 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.07 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 3,670,000 The Company also paid $ 330,000 During the year ended December 31, 2021, the Company issued Common Stock in exchange for convertible debenture and accrued interest. The conversions were within the terms of the agreement with no gain or loss recognized. On April 23, 2021, the Company issued 836,574 100,000 1,644 On April 26, 2021, the Company issued 2,063,391 250,000 3,178 On April 30, 2021, the Company issued 2,058,686 250,000 3,630 338,654 On June 7, 2021, the Company issued 2,431,506 200,000 25,644 On June 23, 2021, the Company issued 2,422,195 200,000 10,247 On July 6, 2021, the Company issued 2,343,919 200,000 7,671 On July 20, 2021, the Company issued 1,664,823 100,000 60,822 On July 29, 2021, the Company issued 3,101,546 200,000 11,836 On August 16, 2021, the Company issued 2,277,273 150,000 6,904 On August 23, 2021, the Company issued 3,454,203 200,000 11,397 On August 30, 2021, the Company issued 2,284,808 150,000 3,082 On September 8, 2021, the Company issued 4,311,269 250,000 6,521 On September 14, 2021, the Company issued 2,936,668 200,000 2,630 On September 20, 2021, the Company issued 4,138,369 250,000 4,095 On October 4, 2021, the Company issued 2,957,622 200,000 2,301 On October 12, 2021, the Company issued 4,205,118 250,000 5,671 On October 25, 2021, the Company issued 3,043,955 200,000 1,205 On November 10, 2021, the Company issued 3,528,221 200,000 5,342 On November 22, 2021, the Company issued 3,561,885 200,000 1,603 On December 6, 2021, the Company issued 5,175,822 250,000 1,027 On December 21, 2021, the Company issued 5,874,062 250,000 35,479 The following represents a summary of the Company’s convertible debt at December 31, 2021: SUMMARY OF CONVERTIBLE DEBT Convertible Note Payable Amounts In-Default Balance – December 31, 2019 - - Proceeds – net 950,000 - Original issue discount 50,000 Debt discount recorded (1,000,000 ) - Amortization of debt discount 50,505 - Balance – December 31, 2020 50,505 - Proceeds – net 4,000,000 - Debt discount recorded (4,000,000 ) - Conversion of debt into common shares (4,250,000 ) Amortization of debt discount 4,702,918 - Balance – December 31, 2021 $ 503,423 $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2019 - - Interest Expense 2020 5,479 Balance – December 31, 2020 5,479 - Interest Expense 2021 238,110 - Interest conversion into common shares (211,932 ) Balance – December 31, 2021 $ 31,657 $ -

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 STOCKHOLDERS’ DEFICIT (A) Common Stock Issued for Cash On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 0.06758 1,000,000 14,797,278 14,797,278 0.06 7,398,639 0.08 ● ½ of all $ 0.06 March 8, 2021 ● ½ of all $ 0.06 March 8, 2022 ● ½ of all $ 0.08 March 8, 2022 ● ½ of all $ 0.08 March 8, 2023 On March 2, 2021, the Company determined to amend and extend the expiration of the warrants expiring on March 8, 2021 as follows: ● 1,479,728 shares of all $ 0.06 Warrants shall expire on March 8, 2021 . ● 1,479,728 shares of all $ 0.06 Warrants shall expire on May 8, 2021 ● 1,479,728 shares of all $ 0.06 Warrants shall expire on July 8, 2021 December 8, 2021 ● 1,479,728 shares of all $ 0.06 Warrants shall expire on September 8, 2021 ● 1,479,727 shares of all $ 0.06 Warrants shall expire on November 8, 2021 On March 2, 2021, the Company issued 1,479,728 1,479,728 88,784 On May 4, 2021, the Company issued 1,479,728 1,479,728 88,784 On December 6, 2021, the Company issued 1,479,728 1,479,728 88,784 (B) Common Stock Issued for Services Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant. On September 3, 2021, the Company issued 3,000,000 242,100 0.0807 (C) Common Stock Warrants and Options On February 24, 2021, the Company issued 70,786 200,000 On March 5, 2021, the Company issued 786,280 2,000,000 On March 2, 2021, the Company issued 1,479,728 1,479,728 88,784 On May 4, 2021, the Company issued 1,479,728 1,479,728 88,784 On December 6, 2021, the Company issued 1,479,728 1,479,728 88,784 On July 30, 2020, the Company issued 9,941,623 10,000,000 On July 8, 2021, the Company issued a 4-year option to purchase 500,000 shares of common stock at an exercise price of $ 0.116 per share to employees for services rendered. The options had a fair value of $ 46,890 , based upon the Black-Scholes option-pricing model on the date of grant and 500,000 options are fully vested on the date granted. SCHEDULE OF OPTION ASSUMPTION Expected dividends 0 % Expected volatility 130.18 % Expected term 4 Risk free interest rate 0.37 % Expected forfeitures 0 % On July 8, 2021, the Company extended the expiration date of the warrant issued on February 9, 2018, to July 8, 2025 100,941 Expected dividends 0 % Expected volatility 130.18 % Expected term 4 Risk free interest rate 0.37 % Expected forfeitures 0 % On April 27, 2021, the Company extended the expiration date of the warrant issued on October 2, 2016 to October 1, 2026 217,715 Expected dividends 0 % Expected volatility 158.54 % Expected term 3 Risk free interest rate 1.37 % Expected forfeitures 0 % On February 2, 2021, the Company extended the expiration date of the warrant to May 29, 2026 85 Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % On January 1, 2016, the Company issued 3-year warrant to purchase 6,000,000 0.001 142,526 May 29, 2026 85 Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % On January 25, 2021, the Company issued a 7-year option to purchase 2,500,000 0.134 310,165 Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company at the end of each successive year for three years. 115,660 Expected dividends 0 % Expected volatility 133.22 % Expected term 7 Risk free interest rate 1.46 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10-year option to purchase 6,000,000 0.115 626,047 Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030 77,988 Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7-year option to purchase 1,340,000 0.115 133,063 Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027. 31,805 20,853 800,000 Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 0.2299 291,842 Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026 51,816 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 0.2299 18,240 Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. 9,133 12,751 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 0.2299 19,525 Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2022. Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. 6,520 9,103 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Balance, December 31, 2019 55,995,917 - 2.77 Granted 3,125,000 - - Exercised (10,000 ) - - Cancelled/Forfeited - - - Balance, December 31, 2020 49,120,917 - 1.83 Granted 8,500,000 - - Exercised (5,439,184 ) - - Cancelled/Forfeited (3,209,454 ) - - Balance, December 31, 2021 48,972,279 - 2.64 Intrinsic Value $ 1,248,451 For the year ended December 31, 2021, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.07 $ 913,900 $ 0.056 1,000,000 3.52 $ 27,900 $ 0.04 2,300,000 4.75 $ 100,970 $ 0.06 7,398,639 0.18 $ 176,827 $ 0.08 3,699,320 0.18 $ 14,427 $ 0.08 3,699,320 1.18 $ 14,427 $ 0.2299 8,250,000 3.21 $ - $ 0.16 3,125,000 4.95 $ - $ 0.25 8,000,000 4.23 $ - $ 0.1160 500,000 3.52 $ - For the year ended December 31, 2020, the following warrants were outstanding: Exercise Price Warrants Weighted Average Remaining Aggregate $ 0.001 11,000,000 1.19 $ 1,371,500 $ 0.056 2,000,000 0.60 $ 139,000 $ 0.04 2,300,000 0.65 $ 196,650 $ 0.06 7,398,639 0.18 $ 484,611 $ 0.06 7,398,639 1.18 $ 484,611 $ 0.08 3,699,320 1.18 $ 168,319 $ 0.08 3,699,320 2.18 $ 168,319 $ 0.2299 8,500,000 4.27 $ - $ 0.16 3,125,000 4.95 $ - For the year ended December 31, 2021, the following options were outstanding: SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 26,802,500 19.11 For the year ended December 31, 2020, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 22,267,800 22.6 (D) Amendment to Articles of Incorporation On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows: ● Common stock Class A, unlimited number of shares authorized, no par value ● Common stock Class B, unlimited number of shares authorized, no par value ● Preferred stock, unlimited number of shares authorized, no par value Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no par value preferred stock. Two shares of Series A Preferred stock have been authorized. (E) Common Stock Issued for Debt On April 23, 2021, the Company issued 836,574 100,000 1,644 On April 26, 2021, the Company issued 2,063,391 250,000 3,178 On April 30, 2021, the Company issued 2,058,686 250,000 3,630 338,654 On June 7, 2021, the Company issued 2,431,506 200,000 25,644 On June 23, 2021, the Company issued 2,422,195 200,000 10,247 On July 6, 2021, the Company issued 2,343,919 200,000 7,671 On July 20, 2021, the Company issued 1,664,823 100,000 60,822 On July 29, 2021, the Company issued 3,101,546 200,000 11,836 On August 16, 2021, the Company issued 2,277,273 150,000 6,904 On August 23, 2021, the Company issued 3,454,203 200,000 11,397 On August 30, 2021, the Company issued 2,284,808 150,000 3,082 On September 8, 2021, the Company issued 4,311,269 250,000 6,521 On September 14, 2021, the Company issued 2,936,668 200,000 2,630 On September 20, 2021, the Company issued 4,138,369 250,000 4,095 On October 4, 2021, the Company issued 2,957,622 200,000 2,301 On October 12, 2021, the Company issued 4,205,118 250,000 5,671 On October 25, 2021, the Company issued 3,043,955 200,000 1,205 On October 28, 2021, the Company issued a 7-year option to purchase 750,000 0.0785 On November 10, 2021, the Company issued 3,528,221 200,000 5,342 On November 22, 2021, the Company issued 3,561,885 200,000 1,603 On December 6, 2021, the Company issued 5,175,822 250,000 1,027 On December 21, 2021, the Company issued 5,874,062 250,000 35,479

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 COMMITMENTS AND CONTINGENCIES On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year period 210,000 6% 281,027 20% 5 297,889 5 315,764 5 398,643 2,991,191 2,804,725 On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to an annual cash compensation of $ 120,000 11,000 three-year 2,000,000 0.001 three-year 3,000,000 0.001 May 28, 2022 121,448 140,000 three-year 6,000,000 0.001 May 20, 2026 the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020. On March 5, 2021, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2022. On February 25, 2022, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2023. 6,000,000 0.2299 20,000 20,000 20,000 As of December 31, 2021 and December 31, 2020, the Company owes $ 3,195 103,730 On October 21, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $ 20,000 On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to annual cash compensation of $ 60,000 three-year 2,000,000 0.2299 1,065 888 (A) License Agreement On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non- refundable license fee of $ 10,000 10,000 13,700 10,000 On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 2% 20 The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $ 5,000 4 265,244 4,025,652 281,659 50,000 On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, 120,000 65,292 1,960 On December 30, 2015, the Company entered into a cooperative agreement for the research and pilot production of hybrid silkworms in Vietnam. Under this agreement, the Company will establish a subsidiary in Vietnam where it will develop and produce hybrid silkworms. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. (B) Operating Lease Agreements Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On May 9, 2019, the Company signed a 5 4,560.57 45,150 On July 1, 2021, the Company signed a 5 6,000 8,645 On January 23, 2017 the Company signed an 8 960 3,683 6,263 On September 13, 2017, the Company signed a new two year lease with a 2 year option commencing on October 1, 2017 and ending on September 31, 2019. The Company paid an annual rent of $ 39,200 42,000 two-year lease 42,000 44,800 42,000 44,800

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 RELATED PARTY TRANSACTIONS On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. Pursuant to the addendum, the Company agreed to issue either 200,000 voting rights equal to 100 common shares per share of preferred stock 120,000 Distinguishing Liabilities from Equity 65,292 7% 1,958 On November 10, 2010, the Company entered into an employment agreement, with its CEO, effective January 1, 2011 through the December 31, 2015. Subsequently, on January 1, 2018 the agreement renewed with the same terms for another 5 398,643 2,991,191 2,804,725 On January 14, 2016, the Company signed a new employment agreement with Mr. Rice, the Company’s COO. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $ 140,000 three-year 6,000,000 0.001 the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice. 20,000 20,000 20,000 As of December 31, 2021 and 2020, the Company owes $ 3,195 103,730 On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to an annual cash compensation of $ 60,000 three-year 2,000,000 0.2299 1,065 888 June 6, 2016, the Company received a $ 50,000 30,000 100,000 15,000 20,000 15,000 15,000 20,000 26,000 11,000 20,000 3,000 30,000 30,000 20,000 20,000 17,000 100,000 100,000 100,000 100,000 100,000 100,000 150,000 100,000 100,000 100,000 30,000 30,000 35,000 70,000 3% 1,657,000 1,657,000 1,657,000 82,851 53,671 50,763 36,562 On January 23, 2017, the Company signed an 8 year property lease with the Company’s President for land in Texas. The Company pays $ 960 3,683 6,263 As of December 31, 2021 and December 31, 2020, there was $ 347,156 331,143 As of December 31, 2021, there was $ 1,703,019 135,908 As of December 31, 2020, there was $ 1,562,499 82,238 As of December 31, 2021, the Company owes $ 2,991,191 3,195 1,065 24,048 As of December 31, 2020, the Company owes $ 2,804,725 103,730 888 22,900 The Company owes $ 65,292

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 SUBSEQUENT EVENTS The Company has analyzed its operations subsequent to March 15, 2022 through the date these financial statements were issued, and has determined that, other than disclosed below, it does not have any material subsequent events to disclose. On January 21, 2022, the Company issued 3,935,417 250,000 2,260 On January 26, 2022, the Company repaid $ 40,000 On January 31, 2022, the Company issued 4,569,059 250,000 42,877 On February 16, 2022, the Company issued 3,924,443 250,000 1,164

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ogranization	(A) Ogranization Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
Foreign Currency	Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
Use of Estimates	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash	Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no
Loss Per Share	Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2021 and 2020, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2021 and 2020 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2021 December 31, 2020 Stock Warrants (Exercise price - $ 0.001 0.25 48,972,277 49,120,917 Stock Options (Exercise price - $ 0.1150 26,802,500 27,340,000 Convertible Debt 6,470,674 - Convertible Preferred Stock 2 2 Total 82,245,453 76,460,919
Research and Development Costs	Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
Income Taxes	Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Expected income tax (recovery) expense at the statutory rate of 21 $ (1,689,619 ) $ (1,043,948 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 1,141,619 608,152 Change in valuation allowance 548,000 435,795 Provision for income taxes $ - $ - The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES 2021 2020 Years Ended December, 2021 2020 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 4,363,336 3,815,336 Valuation allowance (4,343,336 ) (3,815,336 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2041. The net change in the valuation allowance for the year ended December 31, 2021 and 2020 was an increase of $ 548,000 435,795
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. In June 2016, the FASB issued ASU 2016-13 - Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments. Codification Improvements to Topic 326, Financial Instruments – Credit Losses, have been released in November 2018 (2018-19), November 2019 (2019-10 and 2019-11) and a January 2020 Update (2020-02) that provided additional guidance on this Topic. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For SEC filers meeting certain criteria, the amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For SEC filers that meet the criteria of a smaller reporting company (including this Company) and for non-SEC registrant public companies and other organizations, the amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early adoption will be permitted for all organizations for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently in the process of its analysis of the impact of this guidance on its financial statements and does not expect the adoption of this guidance to have a material impact on the Company’s financial statements. In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intra period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard will not have a material effect on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, to reduce complexity in applying U.S. GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2023, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard will not have a material effect on the Company’s financial statements.
Equipment	Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no
Fair Value of Financial Instruments	Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2021 and 2020. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2021 December 31, 2020 Level 1 – Investment in Gold $ 437,212 $ - Level 2 $ - $ - Level 3 $ - $ - Total $ 437,212 $ - The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company. Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter. The following tables summarize activity in gold bullion for the year ended December 31, 2021: SCHEDULE OF GOLD IN BULLION Year Ended December 31, 2021 Ounces Cost Fair Value Beginning balance - $ - $ - Investment in Gold bullion 239 1,884 450,216 Net change in unrealized depreciation - - (13,004 ) Ending balance 239 $ 1,884 $ 437,212
Revenue Recognition	Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017 and ending in September 2018, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the years ended December 31, 2021 and 2020, the Company recognized $ 0 0 On January 25, 2021, the Company signed an amendment to a strategic partnership agreement with Kings Group for and exclusive sales agreement for up to $ 40
Concentration of Credit Risk	Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2021 and December 31, 2020, the Company had approximately $ 2,092,420 500,000
Original Issue Discount	Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt.
Debt Issue Cost	Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.
Beneficial Conversion Feature	Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE	The computation of basic and diluted loss per share for December 31, 2021 and 2020 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2021 December 31, 2020 Stock Warrants (Exercise price - $ 0.001 0.25 48,972,277 49,120,917 Stock Options (Exercise price - $ 0.1150 26,802,500 27,340,000 Convertible Debt 6,470,674 - Convertible Preferred Stock 2 2 Total 82,245,453 76,460,919
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Expected income tax (recovery) expense at the statutory rate of 21 $ (1,689,619 ) $ (1,043,948 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 1,141,619 608,152 Change in valuation allowance 548,000 435,795 Provision for income taxes $ - $ -
SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES	The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES 2021 2020 Years Ended December, 2021 2020 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 4,363,336 3,815,336 Valuation allowance (4,343,336 ) (3,815,336 ) Net deferred tax asset - - Net deferred tax liability $ - $ -
SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS	SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2021 December 31, 2020 Level 1 – Investment in Gold $ 437,212 $ - Level 2 $ - $ - Level 3 $ - $ - Total $ 437,212 $ -
SCHEDULE OF GOLD IN BULLION	The following tables summarize activity in gold bullion for the year ended December 31, 2021: SCHEDULE OF GOLD IN BULLION Year Ended December 31, 2021 Ounces Cost Fair Value Beginning balance - $ - $ - Investment in Gold bullion 239 1,884 450,216 Net change in unrealized depreciation - - (13,004 ) Ending balance 239 $ 1,884 $ 437,212

EQUIPMENT (Tables)

EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	At December 31, 2021 and 2020, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2021 December 31, 2020 Automobile $ 41,805 $ 41,805 Laboratory Equipment 118,890 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 82,739 85,389 Less: Accumulated Depreciation (139,751 ) (141,743 ) Total Property and Equipment, net $ 110,943 $ 89,247

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITITY (Tables)	12 Months Ended
	Dec. 31, 2021
Right To Use Assets And Lease Liabilitity
SCHEDULE OF RIGHT USE OF ASSETS	Right to use assets is summarized below: SCHEDULE OF RIGHT USE OF ASSETS December 31, 2021 Right to use assets, net 70,550 Right to use assets, net 33,574 Total $ 104,124
SCHEDULE OF LEASE LIABILITY	Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY December 31, 2021 Operating lease liability, net 70,550 Operating lease liability, net 33,574 Total 104,124 Less: short term portion (44,577 ) Long term position $ 59,897
SCHEDULE OF LEASE COST	Lease expense for the year ended December 31, 2021 was comprised of the following: SCHEDULE OF LEASE COST Operating lease expense $ 37,461 Operating lease expense $ 55,834 Operating lease expense – related party $ 3,683

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Dec. 31, 2021
Convertible Notes
SCHEDULE OF FAIR VALUE WARRANTS	SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % Stock Price $ 0.15 Exercise price $ 0.25 Expected term (in years) 5 Expected volatility 100.76 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.07 %
SUMMARY OF CONVERTIBLE DEBT	The following represents a summary of the Company’s convertible debt at December 31, 2021: SUMMARY OF CONVERTIBLE DEBT Convertible Note Payable Amounts In-Default Balance – December 31, 2019 - - Proceeds – net 950,000 - Original issue discount 50,000 Debt discount recorded (1,000,000 ) - Amortization of debt discount 50,505 - Balance – December 31, 2020 50,505 - Proceeds – net 4,000,000 - Debt discount recorded (4,000,000 ) - Conversion of debt into common shares (4,250,000 ) Amortization of debt discount 4,702,918 - Balance – December 31, 2021 $ 503,423 $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2019 - - Interest Expense 2020 5,479 Balance – December 31, 2020 5,479 - Interest Expense 2021 238,110 - Interest conversion into common shares (211,932 ) Balance – December 31, 2021 $ 31,657 $ -

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
SCHEDULE OF OPTION ASSUMPTION	SCHEDULE OF OPTION ASSUMPTION Expected dividends 0 % Expected volatility 130.18 % Expected term 4 Risk free interest rate 0.37 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 130.18 % Expected term 4 Risk free interest rate 0.37 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 158.54 % Expected term 3 Risk free interest rate 1.37 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 133.22 % Expected term 7 Risk free interest rate 1.46 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 %
SCHEDULE OF WARRANTS ACTIVITY	SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Balance, December 31, 2019 55,995,917 - 2.77 Granted 3,125,000 - - Exercised (10,000 ) - - Cancelled/Forfeited - - - Balance, December 31, 2020 49,120,917 - 1.83 Granted 8,500,000 - - Exercised (5,439,184 ) - - Cancelled/Forfeited (3,209,454 ) - - Balance, December 31, 2021 48,972,279 - 2.64 Intrinsic Value $ 1,248,451
SCHEDULE OF WARRANTS OUTSTANDING	For the year ended December 31, 2021, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.07 $ 913,900 $ 0.056 1,000,000 3.52 $ 27,900 $ 0.04 2,300,000 4.75 $ 100,970 $ 0.06 7,398,639 0.18 $ 176,827 $ 0.08 3,699,320 0.18 $ 14,427 $ 0.08 3,699,320 1.18 $ 14,427 $ 0.2299 8,250,000 3.21 $ - $ 0.16 3,125,000 4.95 $ - $ 0.25 8,000,000 4.23 $ - $ 0.1160 500,000 3.52 $ - For the year ended December 31, 2020, the following warrants were outstanding: Exercise Price Warrants Weighted Average Remaining Aggregate $ 0.001 11,000,000 1.19 $ 1,371,500 $ 0.056 2,000,000 0.60 $ 139,000 $ 0.04 2,300,000 0.65 $ 196,650 $ 0.06 7,398,639 0.18 $ 484,611 $ 0.06 7,398,639 1.18 $ 484,611 $ 0.08 3,699,320 1.18 $ 168,319 $ 0.08 3,699,320 2.18 $ 168,319 $ 0.2299 8,500,000 4.27 $ - $ 0.16 3,125,000 4.95 $ -
SCHEDULE OF OPTIONS OUTSTANDING	For the year ended December 31, 2021, the following options were outstanding: SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 26,802,500 19.11 For the year ended December 31, 2020, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 22,267,800 22.6

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Convertible preferred stock	82,245,453	76,460,919
Option exercise price	$ 0.1150	$ 0.1150
Stock Warrants [Member]
Convertible preferred stock	48,972,277	49,120,917
Stock Options [Member]
Convertible preferred stock	26,802,500	27,340,000
Convertible Debt [Member]
Convertible preferred stock	6,470,674
Convertible Preferred Stock [Member]
Convertible preferred stock	2	2
Minimum [Member]
Warrant exercise price per share	$ 0.001	$ 0.001
Maximum [Member]
Warrant exercise price per share	$ 0.25	$ 0.25

SCHEDULE OF ANTIDILUTIVE SECU_2

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Option exercise price	$ 0.1150	$ 0.1150
Minimum [Member]
Warrant exercise price per share	0.001	0.001
Maximum [Member]
Warrant exercise price per share	$ 0.25	$ 0.25

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Expected income tax (recovery) expense at the statutory rate of 21%	$ (1,689,619)	$ (1,043,948)
Effective Income Tax Rate Reconciliation, Percent	21.00%	21.00%
Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes)	$ 1,141,619	$ 608,152
Change in valuation allowance	548,000	435,795
Provision for income taxes

SCHEDULE OF DEFERRED TAX ASSE_2

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Effective Income Tax Rate Reconciliation, Percent	21.00%	21.00%

SCHEDULE OF COMPONENTS DEFERRED

SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred tax liability:
Net Operating Loss Carryforward	4,363,336	3,815,336
Valuation allowance	(4,343,336)	(3,815,336)
Net deferred tax asset
Net deferred tax liability

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities	$ 437,212
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities	437,212
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities

SCHEDULE OF GOLD IN BULLION (De

SCHEDULE OF GOLD IN BULLION (Details)	12 Months Ended
	Dec. 31, 2021USD ($)oz	Dec. 31, 2020USD ($)oz
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning balance, ounce | oz
Beginning balance cost
Beginning balalnce, fair value
Investments in gold bullion, ounce | oz	239
Investments in Gold bullion, cost	$ 1,884
Investment in Gold bullion, fair value	$ 450,216
Net change in unrealized depreciation, ounce | oz
Net change in unrealized depreciation, cost
Net change in unrealized depreciation, fair value	$ (13,004)
Ending balance, ounce | oz	239
Ending balance, cost	$ 1,884
Ending balance, fair value	$ 437,212

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash equivalents	$ 0	$ 0
Valuation allowance increase decrease	548,000	435,795
Impairment losses on equipment	0	0
Revenue
Cash excess of FDIC insurance limits	2,092,420	$ 500,000
Exclusive Sales Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 40

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficit	$ 5,796,531
Stockholders' deficiency	5,295,875	$ 6,573,564	$ 5,388,058
Cash used in operating activities	$ 1,800,809	$ 1,254,712

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Less: Accumulated Depreciation	$ (139,751)	$ (141,743)
Total Property and Equipment, net	110,943	89,247
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	41,805	41,805
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	118,890	96,536
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,260	7,260
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 82,739	$ 85,389

EQUIPMENT (Details Narrative)

EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 26,137	$ 28,074
Loss on disposal of asset	$ 49,321	$ 0

SCHEDULE OF RIGHT USE OF ASSETS

SCHEDULE OF RIGHT USE OF ASSETS (Details) - USD ($)	Dec. 31, 2021	Jul. 02, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net	$ 104,124	$ 241,800	$ 365,025
Right To Use Assets Net [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net	70,550
Right To Use Assets Net One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net	$ 33,574

SCHEDULE OF LEASE LIABILITY (De

SCHEDULE OF LEASE LIABILITY (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	$ 104,124
Less: short term portion	(44,577)	$ (124,909)
Long term position	59,897	$ 254,811
Operating Lease Liability Net [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	70,550
Operating Lease Liability Net One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	$ 33,574

SCHEDULE OF LEASE COST (Details

SCHEDULE OF LEASE COST (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	$ 87,874
Operating Lease Expenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	37,461
Operating Lease Expenses One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	55,834
Operating Lease Expenses Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	$ 3,683

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITITY (Details Narrative)	Jul. 02, 2021USD ($)m²	May 09, 2019USD ($)m²	Jan. 23, 2017USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Apr. 16, 2021USD ($)	Apr. 05, 2021USD ($)	Sep. 05, 2019USD ($)ft²	Sep. 13, 2017USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments			$ 960	$ 3,683	$ 13,092
Right of use assets	$ 241,800			104,124	365,025
Lease liabilities				44,577	$ 124,909
Lease term	5 years	5 years						2 years
Area of land | ft²								5,000
Annual rent, year one						$ 42,000		$ 42,000	$ 39,200
Annual rent, year two						$ 44,800		$ 44,800	$ 42,000
Lease expenses				87,874
Socialist Republic Of Vietnam [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | m²	6,000	4,560.57
Annual rent, year one	$ 8,645	$ 45,150
Annual rent, year two		$ 45,150
Rent increase percentage		5.00%
Operating Lease Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments				2,508
Operating Lease Agreements [Member] | Socialist Republic Of Vietnam [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments	$ 8,645
Area of land | m²	6,000	4,560.57
Annual rent, year two		$ 45,150
Removal Of New Guidance [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Right of use assets							$ 44,419
Lease liabilities							$ 44,419
Adoption Of New Guidance [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Right of use assets				79,862
Lease liabilities				$ 79,862

ACCRUED INTEREST _ RELATED PA_2

ACCRUED INTEREST – RELATED PARTY (Details Narrative) - USD ($)	Dec. 01, 2020	Nov. 17, 2020	Nov. 04, 2020	Oct. 19, 2020	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Mar. 02, 2019	Feb. 19, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 08, 2018	Dec. 01, 2017	Jun. 06, 2016	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Proceeds from debt	$ 70,000	$ 35,000	$ 30,000	$ 30,000	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 20,000	$ 100,000	$ 20,000	$ 30,000	$ 30,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000	$ 100,000	$ 30,000	$ 50,000
Debt Instrument, Interest rate																																3.00%
Loans payable amount																															$ 1,657,000	$ 1,657,000
In-kind contribution of interest																															82,851	50,763
Accrued interest																															$ 53,671	$ 36,562
Loan One [Member]
Short-term Debt [Line Items]
Proceeds from debt																			$ 17,000

NOTE PAYABLE (Details Narrative

NOTE PAYABLE (Details Narrative) - USD ($)	Mar. 05, 2021	Apr. 16, 2020	Dec. 31, 2021	Dec. 31, 2020	Jul. 08, 2021	Mar. 01, 2019
Short-term Debt [Line Items]
Notes payable			$ 115,244
Debt instrument, interest rate debt instrument, interest rate				3.00%
Repayment of debt			50,000	$ 40,000
Debt Instrument, Face Amount					$ 180,244
Forgiven percentage	100.00%
Gain on debt extinguishment (PPP)	$ 90,100		90,100
First Six Months [Member]
Short-term Debt [Line Items]
Repayment of debt			1,000
Seven And Eight Months [Member]
Short-term Debt [Line Items]
Repayment of debt			2,000
Nine Through Twenty Three Months [Member]
Short-term Debt [Line Items]
Repayment of debt			5,000
24th Month [Member]
Short-term Debt [Line Items]
Notes payable			180,224
13 Months [Member]
Short-term Debt [Line Items]
Repayment of debt			5,000
14 Months [Member]
Short-term Debt [Line Items]
Notes payable			57,622
20 Months [Member]
Short-term Debt [Line Items]
Notes payable			57,622
Unsecured Promissory Note [Member]
Short-term Debt [Line Items]
Repayment of debt			$ 50,000
Huntington National Bank [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate debt instrument, interest rate		1.00%
Proceeds from Bank Debt		$ 90,100
Debt instrument, maturity date		Apr. 16, 2020
Notre Dame [Member] | Unsecured Promissory Note [Member]
Short-term Debt [Line Items]
Notes payable						$ 265,244
Debt instrument, interest rate debt instrument, interest rate						10.00%

SCHEDULE OF FAIR VALUE WARRANTS

SCHEDULE OF FAIR VALUE WARRANTS (Details)	Dec. 11, 2021$ / shares	Mar. 25, 2021$ / shares	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term	5 years	5 years	5 years
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.14	0.15
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.16	0.25
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	60.64	100.76
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0	0
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.10	0.07

SUMMARY OF CONVERTIBLE DEBT (De

SUMMARY OF CONVERTIBLE DEBT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Balance, beginning	$ 50,505
Proceeds - net	3,670,000	$ 950,000
Balance, end	503,423	50,505
Balance - accrued interest payable	5,479
Balance, In-Default
Interest Expense	238,110	5,479
Interest conversion into common shares	(211,932)
Balance - accrued interest payable	31,657	5,479
Balance, In-Default
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Balance, beginning	50,505
Balance, In-Default
Proceeds - net	4,000,000	950,000
Original issue discount		50,000
Debt discount recorded	(4,000,000)	(1,000,000)
Amortization of debt discount	$ 4,702,918	50,505
Conversion of debt into common shares	(4,250,000)
Balance, end	$ 503,423	50,505
Balance, In-Default

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative)	Dec. 21, 2021USD ($)shares	Dec. 06, 2021USD ($)shares	Nov. 22, 2021USD ($)shares	Nov. 10, 2021USD ($)shares	Oct. 25, 2021USD ($)shares	Oct. 12, 2021USD ($)shares	Oct. 04, 2021USD ($)shares	Sep. 20, 2021USD ($)shares	Sep. 14, 2021USD ($)shares	Sep. 08, 2021USD ($)shares	Aug. 30, 2021USD ($)shares	Aug. 23, 2021USD ($)shares	Aug. 16, 2021USD ($)shares	Jul. 29, 2021USD ($)shares	Jul. 20, 2021USD ($)shares	Jul. 06, 2021USD ($)shares	Jun. 23, 2021USD ($)shares	Jun. 20, 2021USD ($)shares	Jun. 07, 2021USD ($)shares	Apr. 30, 2021USD ($)shares	Apr. 26, 2021USD ($)shares	Apr. 23, 2021USD ($)shares	Apr. 22, 2021USD ($)	Apr. 06, 2021USD ($)	Mar. 25, 2021USD ($)$ / sharesshares	Dec. 11, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)shares	Dec. 11, 2021$ / shares	Jul. 08, 2021USD ($)
Debt Instrument [Line Items]
Debt Instrument, interest rate																												3.00%
Debt instrument, discount																											$ 246,577	$ 949,945
Proceeds from convertible note payable, net of original issue discount																											3,670,000	$ 950,000
Number of warrants issued | shares																									8,000,000			3,125,000
Warrants term																									5 years			5 years	5 years
Fair value of warrants																									$ 3,359,716			$ 2,599,066
Debt face amount																														$ 180,244
Accrued interest																											53,671	36,562
Common Stock [Member]
Debt Instrument [Line Items]
Debt conversion, principal value	$ 250,000	$ 250,000	$ 200,000	$ 200,000	$ 200,000	$ 250,000	$ 200,000	$ 250,000	$ 200,000	$ 250,000	$ 150,000	$ 200,000	$ 150,000	$ 200,000	$ 100,000	$ 200,000	$ 200,000	$ 100,000	$ 200,000	$ 250,000	$ 250,000	$ 100,000
Common shares issued for debt conversion, shares | shares	5,874,062	5,175,822	3,561,885	3,528,221	3,043,955	4,205,118	2,957,622	4,138,369	2,936,668	4,311,269	2,284,808	3,454,203	2,277,273	3,101,546	1,664,823	2,343,919	2,422,195	1,664,823	2,431,506	2,058,686	2,063,391	836,574
Accrued interest	$ 35,479	$ 1,027	$ 1,603	$ 5,342	$ 1,205	$ 5,671	$ 2,301	$ 4,095	$ 2,630	$ 6,521	$ 3,082	$ 11,397	$ 6,904	$ 11,836	$ 60,822	$ 7,671	$ 10,247	$ 60,822	$ 25,644	$ 3,630	$ 3,178	$ 1,644
Fair value of shares issued																				$ 338,654
Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage | $ / shares																									0.15				0.14
Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage | $ / shares																									0.25				0.16
Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage																									100.76				60.64
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage																									0				0
Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage																									0.07				0.10
Unsecured Convertible Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount, Current																											1,000,000
Unsecured Convertible Note [Member]
Debt Instrument [Line Items]
Issuance of convertible securities																										$ 1,000,000
Debt Instrument, interest rate																										10.00%
Percentage of original issue discount																										5.00%
Debt instrument, discount																										$ 50,000
Proceeds from convertible note payable, net of original issue discount																										$ 950,000
Debt instrument, description																										The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date
Debt issuance costs																											$ 330,000	$ 86,000
Unsecured Convertible Note [Member] | First Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt Instrument, interest rate																									10.00%
Debt instrument, discount																									$ 3,670,000
Debt instrument, description																									The note contains a discount to market feature, whereby, the lender can purchase stock at 80% of the lowest trading price for a period of ten (10) days preceding the conversion date
Debt face amount																									$ 4,000,000
Debt conversion, principal value																									$ 500,000
Debt instrument, maturity date																									Mar. 25, 2022
Unsecured Convertible Note [Member] | Secound Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt conversion, principal value																								$ 500,000
Unsecured Convertible Note [Member] | Third Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt conversion, principal value																							$ 3,000,000

SCHEDULE OF OPTION ASSUMPTION (

SCHEDULE OF OPTION ASSUMPTION (Details)	Jul. 08, 2021	Apr. 27, 2021	Feb. 02, 2021	Jan. 25, 2021	Feb. 19, 2020	Aug. 08, 2019	Jan. 02, 2016
Common Stock Warrants and Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends	0.00%
Expected volatility	130.18%
Expected term	4 years
Risk free interest rate	0.37%
Expected forfeitures	0.00%
Common Stock Warrants and Options One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends	0.00%
Expected volatility	130.18%
Expected term	4 years
Risk free interest rate	0.37%
Expected forfeitures	0.00%
Common Stock Warrants and Options Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends		0.00%
Expected volatility		158.54%
Expected term		3 years
Risk free interest rate		1.37%
Expected forfeitures		0.00%
Common Stock Warrants And Options Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends			0.00%
Expected volatility			112.00%
Expected term			5 years
Risk free interest rate			0.18%
Expected forfeitures			0.00%
Common Stock Warrants And Option Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends							0.00%
Expected volatility							112.00%
Expected term							5 years
Risk free interest rate							0.18%
Expected forfeitures							0.00%
Common Stock Warrants And Option Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends				0.00%
Expected volatility				133.22%
Expected term				7 years
Risk free interest rate				1.46%
Expected forfeitures				0.00%
Common Stock Warrants And Option Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends					0.00%
Expected volatility					125.19%
Expected term					3 years
Risk free interest rate					150.00%
Expected forfeitures					0.00%
Common Stock Warrants And Option Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends					0.00%
Expected volatility					125.19%
Expected term					6 years
Risk free interest rate					1.46%
Expected forfeitures					0.00%
Common Stock Warrants and Options Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Expected term						3 years
Risk free interest rate						154.00%
Expected forfeitures						0.00%
Common Stock Warrants And Options Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Expected term						3 years
Risk free interest rate						1.54%
Expected forfeitures						0.00%
Common Stock Warrants And Options Ten [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Expected term						3 years
Risk free interest rate						1.54%
Expected forfeitures						0.00%

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Warrants, Beginning balance	49,120,917	55,995,917
Weighted Average Exercise Price, Beginning balance
Weighted Average Remaining Contractual Life (In Years), Ending balance	2 years 7 months 20 days	1 year 9 months 29 days	2 years 9 months 7 days
Number of Warrants, Granted	8,500,000	3,125,000
Weighted Average Exercise Price, Granted
Number of Warrants, Exercised	(5,439,184)	(10,000)
Weighted Average Exercise Price, Exercised
Number of Warrants, Cancelled/Forfeited	(3,209,454)
Weighted Average Exercise Price, Cancelled/Forfeited
Number of Warrants, Ending balance	48,972,279	49,120,917	55,995,917
Weighted Average Exercise Price, Ending balance
Number of Warrants, Intrinsic Value	$ 1,248,451

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate Intrinsic Value	$ 1,248,451
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.001	$ 0.001
Warrants Exercisable	11,000,000	11,000,000
Weighted Average Remaining Contractual Life	3 years 25 days	1 year 2 months 8 days
Aggregate Intrinsic Value	$ 913,900	$ 1,371,500
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.056	$ 0.056
Warrants Exercisable	1,000,000	2,000,000
Weighted Average Remaining Contractual Life	3 years 6 months 7 days	7 months 6 days
Aggregate Intrinsic Value	$ 27,900	$ 139,000
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.04	$ 0.04
Warrants Exercisable	2,300,000	2,300,000
Weighted Average Remaining Contractual Life	4 years 9 months	7 months 24 days
Aggregate Intrinsic Value	$ 100,970	$ 196,650
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.06	$ 0.06
Warrants Exercisable	7,398,639	7,398,639
Weighted Average Remaining Contractual Life	2 months 4 days	2 months 4 days
Aggregate Intrinsic Value	$ 176,827	$ 484,611
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.08	$ 0.06
Warrants Exercisable	3,699,320	7,398,639
Weighted Average Remaining Contractual Life	2 months 4 days	1 year 2 months 4 days
Aggregate Intrinsic Value	$ 14,427	$ 484,611
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.08	$ 0.08
Warrants Exercisable	3,699,320	3,699,320
Weighted Average Remaining Contractual Life	1 year 2 months 4 days	1 year 2 months 4 days
Aggregate Intrinsic Value	$ 14,427	$ 168,319
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.2299	$ 0.08
Warrants Exercisable	8,250,000	3,699,320
Weighted Average Remaining Contractual Life	3 years 2 months 15 days	2 years 2 months 4 days
Aggregate Intrinsic Value		$ 168,319
Warrant Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.16	$ 0.2299
Warrants Exercisable	3,125,000	8,500,000
Weighted Average Remaining Contractual Life	4 years 11 months 12 days	4 years 3 months 7 days
Aggregate Intrinsic Value
Warrant Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.25	$ 0.16
Warrants Exercisable	8,000,000	3,125,000
Weighted Average Remaining Contractual Life	4 years 2 months 23 days	4 years 11 months 12 days
Aggregate Intrinsic Value
Warrant Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.1160
Warrants Exercisable	500,000
Weighted Average Remaining Contractual Life	3 years 6 months 7 days
Aggregate Intrinsic Value

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Exercise Price	$ 0.115	$ 0.115
Options Outstanding
Options Exercisable	26,802,500	22,267,800
Weighted Average Remaining Contractual Life	19 years 1 month 9 days	22 years 7 months 6 days

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Dec. 21, 2021	Dec. 06, 2021	Nov. 22, 2021	Nov. 10, 2021	Oct. 28, 2021	Oct. 25, 2021	Oct. 12, 2021	Oct. 04, 2021	Sep. 20, 2021	Sep. 14, 2021	Sep. 08, 2021	Sep. 03, 2021	Aug. 30, 2021	Aug. 23, 2021	Aug. 16, 2021	Jul. 29, 2021	Jul. 20, 2021	Jul. 08, 2021	Jul. 06, 2021	Jun. 23, 2021	Jun. 20, 2021	Jun. 07, 2021	May 04, 2021	Apr. 30, 2021	Apr. 26, 2021	Apr. 23, 2021	Mar. 25, 2021	Mar. 05, 2021	Mar. 02, 2021	Feb. 24, 2021	Jan. 25, 2021	Jul. 30, 2020	Feb. 19, 2020	Aug. 08, 2019	Mar. 09, 2019	Jan. 02, 2016	Dec. 31, 2021	Dec. 31, 2020	Jun. 24, 2021	Apr. 27, 2021	Feb. 02, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued		1,479,728																					1,479,728					786,280	1,479,728	70,786		9,941,623
Issuance of common stock in connection with warrant exercise		1,479,728																					1,479,728						1,479,728
Stock issued during period, value		$ 88,784																					$ 88,784						$ 88,784
Issuance of common stock in connection with cashless exercise																												2,000,000		200,000		10,000,000
Fair value of warrants																											$ 3,359,716											$ 2,599,066
Debt Instrument, Increase, Accrued Interest																																					$ 53,671	$ 36,562
Common Class A [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued												3,000,000
Share price												$ 0.0807
Stock issued during period, value												$ 242,100
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price per share																																					$ 0.001	$ 0.001
Issuance of common stock in connection with cashless exercise																																						10,000,000
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price per share																																					0.056	$ 0.056
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price per share																																					0.04	0.04
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price per share																																					0.06	0.06
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price per share																																					$ 0.08	$ 0.06
Common Stock Warrants and Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																		$ 0.116
Options to purchase shares																		500,000
Fair value of options																		$ 46,890
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																		500,000
Common Stock Warrants and Options One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant expiration date																		Jul. 8, 2025
Share based compensation, expense																																					$ 100,941
Common Stock Warrants and Options Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant expiration date																																								Oct. 1, 2026
Share based compensation, expense																																					217,715
Common Stock Warrants And Options Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant expiration date																																									May 29, 2026
Share based compensation, expense																																					85
Common Stock Warrants And Option Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																																				$ 0.001
Warrants to purchase up share																																				6,000,000
Warrant expiration date																																				May 29, 2026
Share based compensation, expense																																					85
Fair value of warrants																																				$ 142,526
Common Stock Warrants And Option Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																															$ 0.134
Options to purchase shares																															2,500,000
Fair value of options																															$ 310,165
Share based compensation, expense																																					115,660
Common stock warrants and options, description																															Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company at the end of each successive year for three years.
Common Stock Warrants And Option Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																																	$ 0.115
Options to purchase shares																																	6,000,000
Fair value of options																																	$ 626,047
Share based compensation, expense																																					77,988
Options description																																	Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030
Common Stock Warrants And Option Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																																	$ 0.115
Options to purchase shares																																	1,340,000
Fair value of options																																	$ 133,063
Share based compensation, expense																																					31,805
Options description																																	Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027.
Options, cancelled, Intrinsic Value																																					$ 20,853
Options expirations in Period, shares																																					800,000
Common Stock Warrants and Options Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																																		$ 0.2299
Options to purchase shares																																		2,000,000
Fair value of options																																		$ 291,842
Share based compensation, expense																																					$ 51,816
Options description																																		Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026
Common Stock Warrants And Options Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																																		$ 0.2299
Options to purchase shares																																		125,000
Fair value of options																																		$ 18,240
Share based compensation, expense																																						$ 9,133
Options description																																		Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.
Warrant Expense																													12,751
Common Stock Warrants And Options Ten [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price																																		$ 0.2299
Options to purchase shares																																		125,000
Fair value of options																																		$ 19,525
Share based compensation, expense																																						$ 6,520
Options description																																		Black-Scholes option-pricing model on the date of grant and are fully vested on August 8, 2022. Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027.
Warrant Expense																													$ 9,103
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price					$ 0.0785
Options to purchase shares					750,000
Debt Conversion, Converted Instrument, Shares Issued	5,874,062	5,175,822	3,561,885	3,528,221		3,043,955	4,205,118	2,957,622	4,138,369	2,936,668	4,311,269		2,284,808	3,454,203	2,277,273	3,101,546	1,664,823		2,343,919	2,422,195	1,664,823	2,431,506		2,058,686	2,063,391	836,574
Debt Conversion, Converted Instrument, Amount	$ 250,000	$ 250,000	$ 200,000	$ 200,000		$ 200,000	$ 250,000	$ 200,000	$ 250,000	$ 200,000	$ 250,000		$ 150,000	$ 200,000	$ 150,000	$ 200,000	$ 100,000		$ 200,000	$ 200,000	$ 100,000	$ 200,000		$ 250,000	$ 250,000	$ 100,000
Debt Instrument, Increase, Accrued Interest	$ 35,479	$ 1,027	$ 1,603	$ 5,342		$ 1,205	$ 5,671	$ 2,301	$ 4,095	$ 2,630	$ 6,521		$ 3,082	$ 11,397	$ 6,904	$ 11,836	$ 60,822		$ 7,671	$ 10,247	$ 60,822	$ 25,644		3,630	$ 3,178	$ 1,644
Fair value of shares issued																								$ 338,654
Purchase Agreement [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																													1,479,728
Warrant exercise price per share																													$ 0.06						$ 0.06
Warrant expiration date																													Mar. 8, 2021						Mar. 8, 2021
Purchase Agreement [Member] | Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																													1,479,728
Warrant exercise price per share																													$ 0.06						$ 0.06
Warrant expiration date																													May 8, 2021						Mar. 8, 2022
Purchase Agreement [Member] | Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																													1,479,728
Warrant exercise price per share																													$ 0.06						$ 0.08
Warrant expiration date																													Jul. 8, 2021						Mar. 8, 2022				Dec. 8, 2021
Purchase Agreement [Member] | Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																													1,479,728
Warrant exercise price per share																													$ 0.06						$ 0.08
Warrant expiration date																													Sep. 8, 2021						Mar. 8, 2023
Purchase Agreement [Member] | Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																													1,479,727
Warrant exercise price per share																													$ 0.06
Warrant expiration date																													Nov. 8, 2021
Purchase Agreement [Member] | Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																																			14,797,278
Share price																																			$ 0.06758
Proceeds from issuance of common stock																																			$ 1,000,000
Purchase Agreement [Member] | Investor [Member] | Class A Common Stock And Two Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																																			14,797,278
Purchase Agreement [Member] | Investor [Member] | 6 Cent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																																			14,797,278
Warrant exercise price per share																																			$ 0.06
Purchase Agreement [Member] | Investor [Member] | 8 Cent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase up share																																			7,398,639
Warrant exercise price per share																																			$ 0.08

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)

Dec. 06, 2021USD ($)shares

Sep. 03, 2021USD ($)shares

Jul. 02, 2021USD ($)m²

May 04, 2021USD ($)shares

Mar. 05, 2021shares

Mar. 02, 2021USD ($)shares

Feb. 24, 2021shares

Jul. 30, 2020shares

Oct. 21, 2019USD ($)

Sep. 05, 2019USD ($)ft²

Aug. 15, 2019USD ($)

Aug. 15, 2019USD ($)

Jul. 03, 2019USD ($)$ / sharesshares

May 09, 2019USD ($)m²

Apr. 26, 2019USD ($)

Mar. 02, 2019shares

Mar. 02, 2019USD ($)

Jan. 09, 2018

Jan. 23, 2017USD ($)

Jan. 14, 2016USD ($)$ / sharesshares

Jan. 14, 2016$ / sharesshares

May 28, 2015$ / sharesshares

Jan. 20, 2015USD ($)$ / sharesshares

Oct. 28, 2011USD ($)shares

Nov. 10, 2010USD ($)

Dec. 26, 2006USD ($)shares

May 08, 2006USD ($)

Jan. 31, 2007USD ($)

Dec. 31, 2021USD ($)$ / shares

Dec. 31, 2020USD ($)$ / shares

Dec. 31, 2019USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 11, 2021

Jul. 08, 2021USD ($)

Apr. 16, 2021USD ($)

Mar. 25, 2021

Aug. 08, 2019$ / sharesshares

Jul. 02, 2019

Sep. 13, 2017USD ($)

Loss Contingencies [Line Items]

Annual salary

$ 734,427

$ 516,332

Accrued salary balance

2,991,191

$ 2,804,725

Number of shares issued | shares

1,479,728

1,479,728

786,280

1,479,728

70,786

9,941,623

Warrants term

5 years

5 years

5 years

Payment for debt

50,000

$ 40,000

Stock issued during period, value

$ 88,784

$ 88,784

$ 88,784

Outstanding balance

$ 180,244

Accrued Interest payable

31,657

5,479

Payments for rent

$ 960

3,683

13,092

Area of land | ft²

5,000

Annual rent, year two

$ 44,800

$ 44,800

$ 42,000

Annual rent, year one

$ 42,000

$ 42,000

$ 39,200

Related Party [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 3,683

$ 6,263

Socialist Republic Of Vietnam [Member]

Loss Contingencies [Line Items]

Area of land | m²

6,000

4,560.57

Annual rent, year two

$ 45,150

Annual rent, year one

$ 8,645

$ 45,150

Maximum [Member]

Loss Contingencies [Line Items]

Warrant exercise price per share | $ / shares

$ 0.25

$ 0.25

Common Class A [Member]

Loss Contingencies [Line Items]

Number of shares issued | shares

3,000,000

Stock issued during period, value

$ 242,100

Mr. Jonathan R. Rice [Member]

Loss Contingencies [Line Items]

Payroll payment

$ 3,195

$ 103,730

Mr Rice [Member]

Loss Contingencies [Line Items]

Payroll payment

3,195

103,730

Mr. Kenneth Le [Member]

Loss Contingencies [Line Items]

Accrued salary balance

1,065

888

Board of Directors Chairman [Member]

Loss Contingencies [Line Items]

Accrued salary balance

1,065

888

Employment Agreement [Member]

Loss Contingencies [Line Items]

Extended expiration date description

the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice.

Employment Agreement [Member] | Chief Executive Officer [Member]

Loss Contingencies [Line Items]

Agreement term description

The term of the agreement is a five year period

Annual salary

$ 210,000

$ 398,643

$ 315,764

$ 297,889

$ 281,027

Annual salary rate, increase

6.00%

Agreement term

5 years

5 years

5 years

5 years

Employment Agreement [Member] | Employee [Member]

Loss Contingencies [Line Items]

Employee bonus rate

20.00%

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]

Loss Contingencies [Line Items]

Annual salary

$ 20,000

$ 20,000

$ 20,000

Annual cash compensation

$ 140,000

$ 120,000

Educational expenses

$ 11,000

Warrants term, description

three-year

three-year

Warrant to purchase common stock shares | shares

6,000,000

6,000,000

6,000,000

Warrant exercise price per share | $ / shares

$ 0.001

$ 0.001

$ 0.2299

Warrants maturity date

May 20, 2026

May 20, 2026

Warrants issued value

$ 121,448

Extended expiration date description

the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020. On March 5, 2021, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2022. On February 25, 2022, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2023.

One-time bonus

$ 20,000

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | January 2015 Warrant [Member]

Loss Contingencies [Line Items]

Warrants term, description

three-year

Warrant to purchase common stock shares | shares

2,000,000

Warrant exercise price per share | $ / shares

$ 0.001

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | May 2015 Warrant [Member]

Loss Contingencies [Line Items]

Warrants term, description

three-year

Warrant to purchase common stock shares | shares

3,000,000

Warrant exercise price per share | $ / shares

$ 0.001

Warrants maturity date

May 28, 2022

Employment Agreement [Member] | Mr. Kenneth Le [Member]

Loss Contingencies [Line Items]

Annual cash compensation

$ 60,000

Warrants term, description

three-year

Warrant to purchase common stock shares | shares

2,000,000

Warrant exercise price per share | $ / shares

$ 0.2299

Salary Increment [Member] | Mr Rice [Member]

Loss Contingencies [Line Items]

Annual salary

$ 20,000

License Agreement [Member]

Loss Contingencies [Line Items]

Agreement term

20 years

License fee

$ 10,000

License maintenance fee

$ 10,000

Annual research fee

$ 13,700

Number of shares issued | shares

2,200,000

Royalty percentage

2.00%

Termination agreement description

The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years.

License termination fee

$ 5,000

Payment for debt

$ 50,000

License Agreement [Member] | Related Party [Member]

Loss Contingencies [Line Items]

Payments for rent

3,683

6,263

License Agreement [Member] | Monthly Rent [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 960

License Agreement [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Annual research fee

$ 10,000

License Agreement [Member] | Common Class A [Member]

Loss Contingencies [Line Items]

Number of shares issued | shares

4,025,652

Payment for debt

$ 265,244

Stock issued during period, value

$ 281,659

Consulting Agreement [Member]

Loss Contingencies [Line Items]

Warrants term

4 years

Royalty and Research Agreements [Member] | Mr. Thompson [Member]

Loss Contingencies [Line Items]

Payment for debt

$ 120,000

Intellectual Property Transfer Agreement [Member] | Mr. Thompson [Member]

Loss Contingencies [Line Items]

Number of shares issued | shares

200,000

Stock issued during period, value

$ 120,000

Outstanding balance

65,292

$ 65,292

Accrued Interest payable

1,960

Operating Lease Agreements [Member]

Loss Contingencies [Line Items]

Payments for rent

2,508

Operating lease, term

8 years

Operating lease term, description

two-year lease

Operating Lease Agreements [Member] | October 1, 2022 through September 30, 2023 [Member]

Loss Contingencies [Line Items]

Payments for rent

44,800

Operating Lease Agreements [Member] | Office and Manufacturing Space [Member] | July One Two Thousand Twenty One And September Thrity Two Thousand Twenty Two [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 42,000

Operating Lease Agreements [Member] | Socialist Republic Of Vietnam [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 8,645

Operating lease description

the Company signed a 5 year property lease with the Socialist Republic of Vietnam which consists of 4,560.57 square meters of space, which it leases at a current rent of approximately $45,150 per year one and two and with the 5% increase per year for years three through five

Operating lease, term

5 years

5 years

Area of land | m²

6,000

4,560.57

Annual rent, year two

$ 45,150

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 06, 2021	May 04, 2021	Mar. 05, 2021	Mar. 02, 2021	Feb. 24, 2021	Dec. 01, 2020	Nov. 17, 2020	Nov. 04, 2020	Oct. 19, 2020	Sep. 10, 2020	Aug. 12, 2020	Jul. 30, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Aug. 15, 2019	Aug. 15, 2019	Jul. 03, 2019	Apr. 26, 2019	Mar. 02, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 09, 2018	Jan. 08, 2018	Dec. 02, 2017	Jan. 23, 2017	Jun. 06, 2016	Jan. 14, 2016	Jan. 14, 2016	Jan. 20, 2015	Nov. 10, 2010	Dec. 26, 2006	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jul. 08, 2021	Aug. 08, 2019
Related Party Transaction [Line Items]
Number of shares issued	1,479,728	1,479,728	786,280	1,479,728	70,786							9,941,623
Stock issued during period, value	$ 88,784	$ 88,784		$ 88,784
Outstanding balance																																																							$ 180,244
Debt Instrument, interest rate																																																		3.00%
Annual salary																																																	$ 734,427	$ 516,332
Accrued salary balance																																																	2,991,191	2,804,725
Paid-in-Kind Interest																																																	82,851	50,763
Debt Instrument, Increase, Accrued Interest																																																	53,671	36,562
Payments for rent																																										$ 960							3,683	13,092
Related Party [Member]
Related Party Transaction [Line Items]
Accrued interest																																																	1,703,019	1,562,499
Payments for rent																																																	3,683	6,263
Loan interest - related party																																																	135,908	82,238
Royalty payable to related party																																																	65,292	65,292
Mr. Jonathan R. Rice [Member]
Related Party Transaction [Line Items]
Payroll payable																																																	3,195	103,730
Mr. Kenneth Le [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																	1,065	$ 888
Stockholder [Member]
Related Party Transaction [Line Items]
Debt Instrument, interest rate																																																		3.00%
Loan received						$ 70,000	$ 35,000	$ 30,000	$ 30,000	$ 100,000	$ 100,000		$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000					$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 17,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000		$ 100,000	$ 30,000		$ 50,000
Loans payable																																																	1,657,000	$ 1,657,000
Chief Executive Officer And Chief Operations Officer [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued expenses																																																	347,156	331,143
Principal Stockholder [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																	2,991,191	2,804,725
Director And Employee [Member]
Related Party Transaction [Line Items]
Payroll payable																																																	3,195	103,730
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																	1,065	888
Office Employees [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																	24,048	22,900
Intellectual Property Transfer Agreement [Member] | Mr. Thompson [Member]
Related Party Transaction [Line Items]
Number of shares issued																																																200,000
Preferred stock voting rights																																																voting rights equal to 100 common shares per share of preferred stock
Stock issued during period, value																																																$ 120,000
Outstanding balance																																																	$ 65,292	$ 65,292
Debt Instrument, interest rate																																																	7.00%
Accrued interest																																																	$ 1,958
Employment Agreement [Member]
Related Party Transaction [Line Items]
Extended expiration date description																																							the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice.
Employment Agreement [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Agreement term																																																	5 years		5 years	5 years	5 years
Annual salary																																															$ 210,000		$ 398,643			$ 315,764	$ 297,889	$ 281,027
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Related Party Transaction [Line Items]
Annual salary																					$ 20,000	$ 20,000		$ 20,000
Annual cash compensation																																												$ 140,000		$ 120,000
Warrants term, description																																												three-year	three-year
Warrant to purchase shares																																												6,000,000	6,000,000											6,000,000
Warrant exercise price per share																																												$ 0.001	$ 0.001											$ 0.2299
Extended expiration date description																																							the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. On March 25, 2019, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2020. On March 5, 2021, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2022. On February 25, 2022, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 1, 2023.
One-time bonus																								$ 20,000
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Related Party Transaction [Line Items]
Annual cash compensation																							$ 60,000
Warrants term, description																							three-year
Warrant to purchase shares																							2,000,000
Warrant exercise price per share																							$ 0.2299
Operating Lease Agreements [Member]
Related Party Transaction [Line Items]
Payments for rent																																																	$ 2,508
Operating Lease Agreements [Member] | President [Member]
Related Party Transaction [Line Items]
Payments for rent																																										$ 960

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Feb. 16, 2022	Jan. 31, 2022	Jan. 26, 2022	Jan. 21, 2022	Dec. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Repayment of debt					$ 50,000	$ 40,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, shares issued	3,924,443	4,569,059		3,935,417
Debt conversion, converted instrument, amount	$ 250,000	$ 250,000		$ 250,000
Interest Payable	$ 1,164	$ 42,877		$ 2,260
Repayment of debt			$ 40,000